Dr. Cheng is an Endocrinologist at Trillium Health Partners and Unity Health Toronto and an Associate Professor at the University of Toronto. Read more
Meet the faculty
Alice Cheng
Lars Rydén (Chair)
Lars Rydén is Senior Professor of Cardiology at the Karolinska Institute, Stockholm, Sweden. He is Dr h.c. at Katowice University, Poland, and Honorary Member of the Royal College of Physicians, UK and of several European Cardiac Societies. Read more
Kevin Saunders
Dr. Kevin Saunders is a family physician in Winnipeg. He completed his medical training at the University of Manitoba in 1985 and has practiced in Winnipeg since then. Read more
Full agenda
Faculty disclosures
Faculty disclosures
Lars Rydén
Advisory board/speaker: Bayer AG, Boehringer-Ingelheim, Eli-Lilly, Novo-Nordisk
Research support: Swedish Heart Lung Foundation, E Persson's Family Foundation, Private Foundations, Stockholm County Council, Boehringer-Ingelheim, Novo-Nordisk
Alice Cheng
Advisory board: Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Insulet, HLS Therapeutics, Janssen, Medtronic, Merck, Novartis, Novo Nordisk, Sanofi, Takeda
Speaking honoraria: Abbott, Astra Zeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eisai, Eli Lilly, HLS Therapeutics, Insulet, Janssen, Medtronic, Merck, Novo Nordisk, Sanofi
Clinical trials: Applied Therapeutics
Kevin Saunders
Grants/research support: BMS, B.I., Novo, Pfizer, Merck, A.Z., Novartis, Bayer, Sanofi
Speakers bureau/honoraria: Merck, B.I., Purdue, Servier, Amgen, Lilly, md Briefcase, CPD Network, ABPHE, McGill CPD Office, Janssen, Pfizer, Novo, A.Z., Bayer
Consulting fees: Pfizer, Janssen, BMS, Servier, B.I., Amgen, Merck, A.Z., Sanofi, Novo, Lilly
Patents: None
Other: None
References
References
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2021;42;3599–3726
Permission provided by the European Cardiology Society to use slides as part of this webinar
Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J 2021;42:681-683
Disclaimer
Disclaimer
Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.